NCT01553032View on ClinicalTrials.gov

Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)

PHASE4CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Head and Neck Cancer
Interventions
DRUG

Erbitux®

400mg/m2 initial dose, followed by weekly doses of 250mg/m2 Treatment duration: 7-8 weeks

RADIATION

Fractionated Radiotherapy

30-35 fractions of radiotherapy (6-7 weeks)

Trial Locations (1)

69120

University of Heidelberg Medical Center, Heidelberg

All Listed Sponsors
collaborator

iOMEDICO AG

INDUSTRY

lead

University of Heidelberg Medical Center

OTHER

NCT01553032 - Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) | Biotech Hunter | Biotech Hunter